EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMAUG00000020019
Gene Symbol: NR3C1
2 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSMAUG00000005964
Gene Symbol: NR3C2
3 Cross references
212 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSMAUG00000004325
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSMAUG00000012704
Gene Symbol: OPRD1
4 Cross references
252 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSMAUG00000001461
Gene Symbol: OPRK1
3 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSMAUG00000016741
Gene Symbol: OPRM1
4 Cross references
214 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSMAUG00000020165
Gene Symbol: OPRL1
3 Cross references
199 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSMAUG00000020582
Gene Symbol: OXTR
4 Cross references
262 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSMAUG00000020347
Gene Symbol: PAK4
4 Cross references
163 Possible Orthologues:

Pancreatic Triacylglycerol Lipase

Ensembl ID : ENSMAUG00000013825
Gene Symbol: LOC101830117
4 Cross references
291 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSMAUG00000022025
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peptidyl-Prolyl Cis-Trans Isomerase A-Like

Ensembl ID : ENSMAUG00000016408
Gene Symbol: LOC101837947
3 Cross references
289 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).